Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
GPRC5D-targeted CAR T (CT071) in relapsed/refractory myeloma finds no DLTs, RP2D 0.1×106 cells/kg, heme toxicities most common G3 or worse TEAEs, CRS in 12 (60%), all of G1-2, 1 (5%) G3 ICANS, ORR 100%, CR or better 50%.”
Title: GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
Authors: Lina Jin, Sinan Gu, Qianqi Ruan, Jing Lu, Wanting Qiang, Haiyan He, Xiaoqiang Fan, Jin Liu, Pei Guo, Xingxing Meng, Nishanthan Rajakumaraswamy, Deng Chen, Zonghai Li, and Juan Du
You can read the Full Article in The Lancet Haematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
